Association of Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 With Endothelial Dysfunction, Cardiovascular Disease Risk Factors and thrombotic events in Children With End-stage Renal Disease

Cardiovascular disease (CVD) is the main cause of death in children with end-stage renal disease (ESRD). Matrix metalloproteinases (MMP-2 and MMP-9) are members of endopeptidases which contribute to CVD. The aim of this study was to evaluate the association of MMP-2 and MMP-9 with markers of endothelial dysfunction, soluble E-selectin and brachial flow-mediated dilatation; several biochemical risk factors of CVD; and thrombotic incidents in children with ESRD. Thirty-one children with ESRD and 18 healthy age- and sex-adjusted controls underwent measurement of serum levels of MMP-2, MMP-9, soluble E-selectin, phosphorus, calcium, parathyroid hormone, lipid profile, thrombotic factors, and albumin. Flow-mediated dilatation was measured in both groups by Doppler ultrasonography. Thrombotic events were assessed in patients with ESRD. Matrix metalloproteinase-2 positively correlated with systolic and diastolic blood pressure, soluble E-selectin, creatinine, cholesterol, triglyceride, low-density lipoprotein cholesterol, phosphorus, and parathyroid hormone and negatively correlated with body mass index, hemoglobin, high-density lipoprotein cholesterol, and flow-mediated dilatation, while MMP-9 correlated with soluble E-selectin, phosphorus, parathyroid hormone, and albumin and negatively correlated with body mass index and hemoglobin. Six patients (19.3%) had thrombotic incidents. There was no significant difference between the levels of MMP-2 and MMP-9 in the children with and without thrombotic events. This study determined the associations of MMP-2 and MMP-9 with markers of endothelial dysfunction and several traditional and uremia related CVD risk factors in children with ESRD. No associations were found between these two MMPs and thrombotic events.